



**ANNUAL MEETING PROGRAMME**

**Friday 14<sup>th</sup> October 2016**

08.00-09.15	Tea/Coffee/Scones/Meet the Sponsors
09.15	Opening of the Annual HAI Meeting – Dr Eibhlin Conneally, President
09.30-11.15	SESSION 1 – Oral Presentations Chairpersons: Dr Irene Regan & Dr Gary Benson
09.30-09.40	A survey of the treatment of the prevention of NAIT in the UK and Ireland Valerie Broderick <sup>1</sup> , D O'Keeffe <sup>1</sup> <sup>1</sup> Department of Haematology, University Hospital Limerick, Limerick
09.40-09.50	ANALYSIS OF THE SIDE EFFECT PROFILE OF TKIs IN PATIENTS WITH CML IN BEAUMONT HOSPITAL OVER A 10 YEAR PERIOD. Jennifer G Garry <sup>1</sup> , PM Murphy <sup>1</sup> , JQ Quinn <sup>1</sup> , PT Thornton <sup>1</sup> . <sup>1</sup> Haematology, Beaumont Hospital, Dublin.
09.50-10.00	N-linked glycans within the A2 domain of VWF play a critical role in modulating macrophage-mediated clearance. Jamie M O'Sullivan <sup>1,2</sup> , A Chion <sup>1,2</sup> , C Drakeford <sup>1,2</sup> , N Dalton <sup>1,2</sup> , S Ward <sup>1,2</sup> , T Brophy <sup>1,2</sup> , JS O'Donnell <sup>1,2</sup> . <sup>1</sup> Irish Centre for Vascular Biology, Royal College of Surgeons, Dublin, <sup>2</sup> Haemostasis Research Group, Institute of Molecular Medicine, Trinity College Dublin.
10.00-10.10	O-LINKED SIALYLATION ON HUMAN VWF PLAYS A CRITICAL ROLE IN MODULATING IN VIVO CLEARANCE THROUGH NOVEL MACROPHAGE-MEDIATED PATHWAYS. Sorcha E. Ward <sup>1</sup> , J M. O'Sullivan <sup>1,2</sup> , N Dalton <sup>1</sup> , C Drakeford <sup>1</sup> , A Chion <sup>1,2</sup> , J S. O'donnell <sup>1,2</sup> <sup>1</sup> Haemostasis Research Group, Trinity College Dublin, Dublin, <sup>2</sup> Irish Centre for Vascular Biology, Royal College of Surgeons, Dublin.
10.10-10.20	THE ROLE OF MARROW FIBROSIS IN THE PROGNOSIS AND TREATMENT OF MYELODYSPLASIC SYNDROMES: A SINGLE CENTRE RETROSPECTIVE STUDY Emma M Groarke <sup>1</sup> , S Maung <sup>1</sup> , K Ewins <sup>1</sup> , M Jeffers <sup>2</sup> , J McHugh <sup>1</sup> , R Desmond <sup>1</sup> , H Enright <sup>1</sup> <sup>1</sup> Department of Haematology, Tallaght Hospital, Tallaght, Dublin 24, <sup>2</sup> Department of Pathology, Tallaght Hospital, Tallaght, Dublin 24
10.20-10.30	TURNING THE HEAT UP A NOTCH IN BICLONAL LYMPHOPROLIFERATIVE DISORDERS Helen Fogarty <sup>1,2</sup> , A Dowling <sup>1,2</sup> , D O'Brien <sup>2</sup> , CL Bacon <sup>2</sup> , P Thornton <sup>3</sup> , B Hennessy <sup>4</sup> , H O'Leary <sup>5</sup> , G Crotty <sup>6</sup> , R Henderson <sup>6</sup> , J Nolan <sup>5</sup> , E Vandenberghe <sup>1,2</sup> , F Quinn <sup>1</sup> <sup>1</sup> Department of Cancer Molecular Diagnostics, St. James's Hospital and Trinity College , Dublin, <sup>2</sup> Department of Haematology, St James Hospital and Trinity College , Dublin, <sup>3</sup> Department of Haematology, Beaumont Hospital, Dublin, <sup>4</sup> Department of Haematology, Waterford Regional Hospital, Waterford, <sup>5</sup> Department of Haematology, University Hospital Limerick, Limerick, <sup>6</sup> Department of Haematology, Midlands Regional Hospital, Tullamore.
10.30-11.10	STATE OF THE ART LECTURE - Chairperson: Dr Eibhlin Conneally  <i>'SICKLE CELL DISEASE IN IRISH ADULTS - A NEW CHALLENGE'</i> Dr Emma Tuohy, Consultant Haematologist, St James's Hospital, Dublin
11.10-11.40	TEA/COFFEE/POSTERS AND MEET THE SPONSORS



**ANNUAL MEETING PROGRAMME**

**Friday 14<sup>th</sup> October 2016**

11.40-12.25	<b>Session 2: Chairpersons:</b>
11.40-12.25	<b>STATE OF THE ART LECTURE: Chairperson: Dr Ronan Desmond</b>  <b><i>THE EVER CHANGING GENOMIC LANDSCAPE OF ACUTE LYMPHOBLASTIC LEUKAEMIA AND OPPORTUNITIES FOR TARGETED THERAPY</i></b> <b>Dr Anthony Moorman, Professor of Genetic Epidemiology at the Northern Institute for Cancer Research, Newcastle University</b>
12.25-12.55	<b>HAEMATOLOGY SPECIALIST TRAINING COMMITTEE MEETING – Dr Jeremy Sargent</b> <b>Trainers and Trainee Representatives Welcome</b>
12.25-13.40	<b>LUNCH</b>
13.40-15.30	<b>SESSION 3: Oral Presentations – Chairpersons: Dr Ruth Gilmore &amp; Dr Gerry Crotty</b>
13.40-13.50	<b>FASTING BLOOD TESTS AND UNNECESSARY HAEMATOLOGY REFERRALS</b> <b>Dawn Swan<sup>1</sup>, B Hennessy<sup>1</sup>, E Elhassadi<sup>1</sup>, S Kumar<sup>1</sup>, T Walsh<sup>1</sup></b> <sup>1</sup> University Hospital Waterford, Waterford
13.50-14.00	<b>THE BINDING OF VWF AUGMENTS MACROPHAGE TLR (2/4) SIGNALLING – AN EMERGING ROLE FOR VWF IN MACROPHAGE BIOLOGY.</b> <b>Clive Drakeford<sup>1,3</sup>, FJ Sheedy<sup>2</sup>, S Basdeo<sup>2</sup>, A Chion<sup>3</sup>, S Aguila<sup>1,3</sup>, J O'Sullivan<sup>3</sup>, S Ward<sup>1,3</sup>, N Dalton<sup>1</sup>, M Lavin<sup>1,3</sup>, T Brophy<sup>1</sup>, J Keane<sup>2</sup>, J O'Donnell<sup>1,3</sup></b> <sup>1</sup> Hemostasis, Trinity College Dublin, Dublin, Ireland <sup>2</sup> TB Immunology, Trinity College Dublin, Dublin, Ireland <sup>3</sup> Hemostasis, Royal College of Surgeons, Dublin, Ireland
14.00-14.10	<b>PLATELET VON WILLEBRAND FACTOR LEVELS PROVIDE NOVEL INSIGHTS INTO THE BIOLOGY UNDERLYING QUANTITATIVE VON WILLEBRAND DISEASE.</b> <b>Niall Dalton<sup>1,2</sup>, S Aguila<sup>2,3</sup>, S Schneppenheim<sup>4</sup>, JM O'Sullivan<sup>2,3</sup>, NM O'Connell<sup>1</sup>, K Ryan<sup>1</sup>, M Byrne<sup>1</sup>, MM Doyle<sup>1</sup>, M Nolan<sup>1</sup>, U Budde<sup>4</sup>, P James<sup>5</sup>, J Di Paola<sup>6</sup>, JS O'Donnell<sup>1,2,3</sup>, M Lavin<sup>1,2,3</sup></b> <sup>1</sup> National Centre for Hereditary Coagulation Disorders, St James's Hospital, Dublin, <sup>2</sup> Haemostasis Research Group, Trinity College Dublin, Dublin, <sup>3</sup> Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, <sup>4</sup> MEDILYS Laborgesellschaft mbH, ASKLEPIOS Klinik Altona, Zentrales Labor, Paul-Ehrlich-Strasse 1, 22763 Hamburg, Germany <sup>5</sup> Department of Medicine, Queen's University, Kingston, Ontario, Canada <sup>6</sup> Department of Pediatrics and Human Genetics and Genomics Program, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA
14.10-14.25	<b>HFE MUTATIONS IN IDIOPATHIC ERYTHROCYTOSIS</b> <b>G BIAGETTI<sup>1</sup>, NUALA ROBSON<sup>2</sup>, MA CATHERWOOD<sup>2</sup>, I BERTOZZI<sup>2</sup>, E COSI<sup>2</sup>, ML RANDI<sup>2</sup>, MF MCMULLIN<sup>1</sup></b> <sup>1</sup> Clinica Medica 1, Dept. of Medicine –DIMED, Padova, Italy, <sup>2</sup> Haematology, Belfast City Hospital, Belfast, UK
14.25-15.10	<b>STATE OF THE ART LECTURE – Chairperson: Dr Kathryn Boyd</b>  <b><i>“EMERGENCE OF NEW DIAGNOSTICS IN MDS”</i></b> <b>Dr Catherine Cargo, Consultant Haematologist,</b> <b>St James's University Hospital, Leeds</b>
15.10-15.40	<b>TEA/COFFEE/POSTERS AND MEET THE SPONSORS</b>



**ANNUAL MEETING PROGRAMME**

**Friday 14<sup>th</sup> October 2016**

<b>15.40-17.00</b>	<b>PRESIDENT'S SYMPOSIUM – Chairpersons: Dr Moulod El-Agnaf &amp; Dr Eibhlin Conneally</b>
<b>15.40-15.55</b>	<b>MYELOPROLIFERATIVE NEOPLASM PATIENT SYMPTOMBURDEN AND QUALITY OF LIFE: EVIDENCE OF SIGNIFICANT IMPAIRMENT COMPARED TO CONTROLS USING MULTIVARIATE ANALYSIS</b> <b>LA Anderson<sup>1</sup></b> , G James <sup>1</sup> , AC Dueck <sup>2</sup> , AS Duncombe <sup>3</sup> , R Mesa <sup>2</sup> , RM Scherber <sup>4</sup> , HE Kosiorek <sup>2</sup> , F DeVocht <sup>5</sup> , M Clarke <sup>1</sup> , MF McMullin <sup>6</sup> <sup>1</sup> Centre for Public Health, Queen's University Belfast, Belfast, UK <sup>2</sup> Mayo Clinic Cancer Centre, Mayo Clinic, Scottsdale/Phoenix, USA <sup>3</sup> Department of Haematology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK, <sup>4</sup> Hematology and Oncology, Oregon Health and Sciences University, Portland, USA, <sup>5</sup> School of Social and Community Medicine, University of Bristol, Bristol, UK <sup>6</sup> Centre for Cancer Research and Cell Biolog, Queen's University Belfast, Belfast, UK
<b>15.55-16.10</b>	<b>NOVEL INSIGHTS INTO THE CLINICAL PHENOTYPE AND PATHOPHYSIOLOGY UNDERLYING LOW VWF LEVELS: THE LOW VON WILLEBRAND FACTOR IRELAND COHORT (LOVIC) STUDY</b> <b>M Lavin<sup>1,2,3</sup></b> , S Aguila <sup>2,3</sup> , S Schneppenheim <sup>4</sup> , N Dalton <sup>1,2</sup> , JM O'Sullivan <sup>2,3</sup> , NM O'Connell <sup>1</sup> , K Ryan <sup>1</sup> , M Byrne <sup>1</sup> , M Rafferty <sup>1</sup> , M Nolan <sup>1</sup> , U Budde <sup>4</sup> , P James <sup>5</sup> , J Di Paola <sup>6</sup> , JS O'Donnell <sup>1,2,3</sup> <sup>1</sup> National Centre for Hereditary Coagulation Disorders, St James's Hospital, Dublin, <sup>2</sup> Haemostasis Research Group, Trinity College Dublin, Dublin, <sup>3</sup> Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, <sup>4</sup> MEDILYS Laborgesellschaft mbH, ASKLEPIOS Klinik Altona, Zentrales Labor, Paul-Ehrlich-Strasse 1, 22763 Hamburg, Germany <sup>5</sup> Department of Medicine, Queen's University, Kingston, Ontario, Canada <sup>6</sup> Department of Pediatrics and Human Genetics and Genomics Program, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA.
<b>16.10-16.25</b>	<b>MINIMAL RESIDUAL DISEASE (MRD) STATUS IN FCR-TREATED CLL PATIENTS AT THE END OF TREATMENT INFLUENCES PROGRESSION FREE SURVIVAL (PFS): RESULTS OF THE CTrial-IE (ICORG) 07-01/ CLL IRELAND STUDY WITH MUTATIONAL ANALYSIS PROVIDING ADDITIONAL INSIGHT</b> <b>Niamh Appleby<sup>1</sup></b> , F Quinn <sup>2</sup> , D O'Brien <sup>3</sup> , L Smyth <sup>1</sup> , J Kelly <sup>4</sup> , I Parker <sup>5</sup> , K Scott <sup>5</sup> , M Cahill <sup>6</sup> , G Crotty <sup>7</sup> , H Enright <sup>8</sup> , B Hennessy <sup>9</sup> , A Hodgson <sup>10</sup> , M Leahy <sup>11</sup> , H O'Leary <sup>11</sup> , M O'Dwyer <sup>12</sup> , A Hayat <sup>12</sup> , E Vandenberghe <sup>1</sup> <sup>1</sup> Haematology, St James's University Hospital, Dublin 8, <sup>2</sup> Cancer Molecular Diagnostics, St James's University Hospital, Dublin 8, <sup>3</sup> Immunophenotyping, St James's University Hospital, Dublin 8, <sup>4</sup> National Centre for Medical Genetics, Our Ladys Childrens Hospital Crumlin, Dublin 12, <sup>5</sup> Haematology, Cork University Hospital, Cork, <sup>6</sup> Haematology, Midlands Regional Hospital, Tullamore, <sup>7</sup> Haematology, Adelaide Meath and National Childrens Hospital, Tallaght, <sup>8</sup> Haematology, Waterford Regional Hospital, Waterford, <sup>9</sup> Haematology, Sligo Regional Hospital, Sligo, <sup>10</sup> Haematology, Limerick University Hospital, Limerick, <sup>11</sup> Haematology, University Hospital Galway, Galway
<b>16.25-16.40</b>	<b>COMPLICATIONS ASSOCIATED WITH CENTRAL VENOUS ACCESS DEVICES IN CHILDREN WITH SEVERE HAEMOPHILIA: A 12 YEAR REVIEW</b> <b>Niamh O' Brien<sup>1</sup></b> , B Antao <sup>2</sup> , B Nolan <sup>1</sup> , C Ryan <sup>3</sup> <sup>1</sup> Haematology Department, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland <sup>2</sup> Surgical Department, Our Lady's Children's Hospital, Crumlin, Dublin 12, Ireland <sup>3</sup> Paediatric Department, Cork University Hospital, Cork, Ireland
<b>16.40-16.55</b>	<b>EVALUATION OF METHODS TO MITIGATE THE INTERFERENCE CAUSED BY DARATUMUMAB IN PRE-TRANSFUSION SEROLOGICAL TESTING.</b> <b>Edel Scally<sup>1</sup></b> , J Long <sup>1</sup> , B Doyle <sup>1</sup> , S NiLoingsigh <sup>1</sup> <sup>1</sup> Diagnostics Laboratory, Irish Blood Transfusion Service, James's St. Dublin 8.



<b>ANNUAL MEETING PROGRAMME</b> <b>Friday 14<sup>th</sup> October 2016</b>	
17.00-18.00	LIAM O'CONNELL LECTURE – Chairperson: Dr Dairmaid O'Donghaile  “BLOOD TRANSFUSION: PRECISION VERSUS IMPRECISION MEDICINE” Dr Harvey G Klein, Chief, Department of Transfusion Medicine, National Institutes of Health, Bethesda, MD, USA
18.15-19.30.	OFFICIAL POSTER VIEWING
20.00	EVENING DINNER –Radisson Hotel

## **FRIDAY 14<sup>th</sup> OCTOBER, 2016**

**Time: 14.00-17.30**

### **Laboratory Science Session**

Guest Lecture:

“Molecular Monitoring of CLL”

Dr Mark Catherwood, Belfast City Hospital, Belfast

**Time: 18.15-19.45**

### **Poster Board Presentations**

(Refreshments and Canapes will be served during the Poster Board Presentation Walkabout and Adjudication)

**Time: 19.30**

**Gala Dinner, Radisson Hotel, Athlone**



**ANNUAL MEETING PROGRAMME**  
**SATURDAY 15<sup>TH</sup> OCTOBER 2016**

09.00-09.30	<b>Annual General Meeting – All Welcome</b>
09.30-10.40	<b>Oral Presentations – Chairpersons: Dr Roger Preston &amp; Dr Ronan Desmond</b>
09.30-09.40	<b>TITLE TO BE CONFIRMED</b> <b>Barry Kevane<sup>1-3</sup>, K Egan<sup>1,2</sup>, S Allen<sup>1,2</sup>, PB Maguire<sup>4</sup>, Á Lennon<sup>3</sup>, E Neary<sup>5</sup>, F Ní Áinle<sup>1-3</sup></b> <sup>1</sup> School of Medicine and Medical Science, University College Dublin, Dublin, <sup>2</sup> SPHERE Research Group, UCD Conway Institute, Dublin, <sup>3</sup> Haematology, Mater Misericordiae University Hospital, Dublin, <sup>4</sup> School of Biomolecular and Biomedical Science, University College Dublin, Dublin, <sup>5</sup> Neonatology, Rotunda Hospital, Dublin, Ireland.
09.40-09.50	<b>CLINICAL OUTCOMES IN A COHORT OF HIGH RISK MYELOID MALIGNANCIES TREATED WITH REDUCED INTENSITY CONDITIONED (FLAMSA-BU) ALLOGENEIC STEM CELL TRANSPLANT (ALLO-SCT).</b> <b>Chris Armstrong<sup>1</sup>, N Appleby<sup>1</sup>, M Ni Chonghaile<sup>1</sup>, G Lee<sup>2</sup>, K Haslam<sup>3</sup>, CM Flynn<sup>1</sup>, E Conneally<sup>1</sup>.</b> <sup>1</sup> Dept. of Haematology, St. James' University Hospital, Dublin, <sup>2</sup> European Blood and Marrow Transplantation, St. James' University Hospital, Dublin, <sup>3</sup> Cancer Molecular Diagnostics, St. James' University Hospital, Dublin,
09.50-10.00	<b>Potential of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib Via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCC</b> <b>A Rigalou<sup>1</sup>, A Ryan<sup>1</sup>, A Natoni<sup>1</sup>, C Chiu<sup>2</sup>, K Sasser<sup>2</sup>, Michael O'Dwyer<sup>3</sup></b> <sup>1</sup> Biosciences, NUI Galway, Galway, Ireland, <sup>2</sup> Oncology Heme Translational Research Group, Research and Development, Janssen, Spring House PA, USA, <sup>3</sup> Haematology, NUI Galway, Galway, Ireland
10.00-10.10	<b>Glycosylation Gene Signature in Multiple Myeloma predicts survival and identifies potential candidates for targeted therapy (GiMM13)</b> <b>Caoilfhionn M Connolly<sup>1</sup>, J Alokumar<sup>2</sup>, A Natoni<sup>1</sup>, ME O'Dwyer<sup>1</sup></b> <sup>1</sup> Department of Hematology,, National University of Ireland, Galway, Galway, Ireland <sup>2</sup> Insight Centre for Data Analytics, National University of Ireland, Galway, Galway
10.10-10.20	<b>Implications of introducing an electronic blood transfusion system</b> <b>Deirdre Gough, C Finucane, J Mc Cabe, AM Mc Cann, D Ó Donghaile</b> <sup>1</sup> Blood Transfusion Laboratory, St James's Hospital, Dublin
10.20-10.30	<b>CORRELATION OF SEROLOGICAL ANTI-D REACTION STRENGTH BY INDIRECT ANTIGLOBULIN TECHNIQUE TO ANTI-D QUANTITATION LEVEL.</b> <b>M Keogh<sup>1</sup>, B Doyle<sup>1</sup>, S Ni Loingsigh<sup>1</sup></b> <sup>1</sup> Diagnostics Laboratory, Irish Blood Transfusion Service, James's St. Dublin 8.
10.30-10.40	<b>Development of a Next Generation Sequencing approach to simultaneously detect the common Myeloproliferative Neoplasm-associated mutations in JAK2, CALR, and MPL.</b> <b>Thomas Frawley<sup>1</sup>, C O'Brien<sup>1</sup>, M Percy<sup>2</sup>, E Conneally<sup>3</sup>, E Vandenberghe<sup>1,3</sup>, S Langabeer<sup>1</sup>, K Haslam<sup>1</sup>.</b> <sup>1</sup> Cancer Molecular Diagnostics, St. James's Hospital, Dublin, Ireland <sup>2</sup> Department of Haematology, Belfast City Hospital, Belfast, UK <sup>3</sup> Department of Haematology, St. James's Hospital, Dublin, Ireland
10.40.10.50	<b>THE ROLE OF CLINICAL TRIALS IN REDUCING THE ECONOMIC BURDEN OF HAEMATOLOGICAL MALIGNANCIES</b> <b>Cian McEllistrim<sup>1</sup>, J Given<sup>2</sup>, L Broderick<sup>2</sup>, M Byrne<sup>3</sup>, A Hayat<sup>1</sup>, J Krawczyk<sup>1</sup>, M Murray<sup>1</sup>, R Gilmore<sup>1</sup>, M O'Dwyer<sup>1</sup>.</b> <sup>1</sup> Haematology Dept., University Hospital Galway, Galway, <sup>2</sup> Pharmacy Dept., University Hospital Galway, Galway, <sup>3</sup> Cancer Trials Ireland, University Hospital Galway, Galway
10.50-11.00	<b>Polyclonal IgG N-glycosylation in the pathogenesis of plasma cell disorders.</b> <b>S Mittermayr<sup>1</sup>, Gao N Le<sup>1,2,3</sup>, C Clarke<sup>1</sup>, SM Martin<sup>1</sup>, AM Larkin<sup>3</sup>, P O'Gorman<sup>2</sup>, J Bones<sup>1</sup></b> <sup>1</sup> Glycobiology, The National Institute for Bioprocessing Research and Training, Blackrock, County Dublin, <sup>2</sup> Haematology, Mater Misericordiae University Hospital, Dublin, <sup>3</sup> National Institute for Cellular Biotechnology, Dublin City University, Dublin



<b>ANNUAL MEETING PROGRAMME</b> <b>SATURDAY 15<sup>TH</sup> OCTOBER 2016</b>	
<b>11.00-11.25</b>	<b>TEA/COFFEE AND MEET THE SPONSORS</b>
<b>11.25-11.55</b>	<b>STATE OF THE ART LECTURE – Chairperson: Dr Roger Preston</b>  <b>“THE CONTACT SYSTEM: CROSSTALK OF COAGULATION AND INFLAMMATION”</b> <b>Thomas Renné, MD, PhD</b> Professor of Clinical Chemistry Department of Molecular Medicine and Surgery Karolinska Institutet and University Hospital Solna, Sweden
<b>11.55-12.10</b>	<b>Fellowship Update – Karl Haslam, 2014 Winner</b>
<b>12.10-12.40</b>	<b>STATE OF THE ART LECTURE – Chairperson: Dr Eibhlin Conneally</b>  <b>“TREATMENT OF B-CELL MALIGNANCIES IN THE AGE OF PRECISION MEDICINES”</b> <b>Professor Martin Dyer, Professor of Haemato-Oncology and Honorary Consultant</b> Physician, Department of Haematology Director of the Ernest and Helen Scott Haematological Research Institute, University of Leicester
<b>12.40-12.50</b>	<b>Prizes and Close of Meeting</b>
<b>12.50-14.30</b>	<b>Lunch and Quiz</b>

**SATURDAY 15<sup>th</sup> OCTOBER, 2016**

**Time: 14.30-17.00**

**Education Session for SpRs, Registrars & Trainees in  
Haematology**